Summary & Overview
HCPCS G9110: Head and Neck Cancer Disease-Status Assessment
HCPCS Level II code G9110 designates a disease-status determination for head and neck cancers of the oral cavity, pharynx, and larynx when squamous cell carcinoma is the predominant histology and initial staging is t3-4 and/or n1-3, m0. The code is specified for use in a Medicare-approved demonstration project and signals a structured assessment documenting no evidence of progression, recurrence, or metastases prior to neo-adjuvant therapy (if any). Nationally, such codes support standardized reporting of oncologic status in clinical trials, demonstration projects, and care coordination initiatives.
Payors covered in this analysis include major national commercial insurers and public payer programs: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical intent, typical sites of service, and where this code fits into oncology documentation workflows. The publication outlines expected use cases for demonstration projects, clarifies clinical scope, and flags where input data are limited. It also provides benchmarking and policy-oriented content relevant to payers and provider organizations, and explains implications for coding, billing, and program reporting when G9110 is applied.
Billing Code Overview
HCPCS Level II code G9110 describes a disease status assessment for head and neck cancer, limited to cancers of the oral cavity, pharynx and larynx where squamous cell is the predominant histology. The descriptor specifies that the extent of disease was initially established as t3-4 and/or n1-3, m0 prior to any neo-adjuvant therapy, and that there is no evidence of disease progression, recurrence, or metastases. This code is intended for use in a Medicare-approved demonstration project.
Service type: Oncology disease-status assessment and documentation
Typical site of service: Oncology clinic or hospital outpatient setting, including specialized head and neck cancer clinics and multidisciplinary cancer centers.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with a history of tobacco and alcohol use presents after biopsy-confirmed squamous cell carcinoma of the lateral tongue. Staging workup including contrast-enhanced CT of the neck and chest, PET-CT, and clinical exam establishes tumor extent as T3 (tumor >4 cm or with minor adjacent structure invasion), N2 disease (ipsilateral multiple lymph nodes >3 cm but ≤6 cm), and M0. The multidisciplinary head and neck oncology team documents no evidence of distant metastases and no interval progression after diagnostic imaging and prior diagnostic biopsy. The patient is being enrolled in a Medicare-approved demonstration project assessing outcomes for advanced head and neck squamous cell carcinoma prior to any neoadjuvant therapy. Clinical workflow steps include diagnostic biopsy and pathology confirmation, staging imaging, tumor board review confirming extent of disease as T3-4 and/or N1-3, M0, informed consent for enrollment in the demonstration project, baseline documentation of no progression or metastasis, and scheduling of definitive therapy (surgery, radiation, and/or systemic therapy) per protocol. Typical site of service is an outpatient specialty oncology clinic or hospital-based multidisciplinary clinic with coordination to inpatient surgical services if operative management is planned.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |